Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 14 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 7569580

    Heterotricyclic compounds for use as HCV inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Aug 4, 2009 · Expires Jul 30, 2029

    granted

  2. US 7566732

    Rhodanine compositions for use as antiviral agents

    Rigel Pharmaceuticals, Inc. · Granted Jul 28, 2009 · Expires Jul 23, 2029

    granted

  3. US 7563892

    Prodrugs of 2,4 pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 21, 2009 · Expires Jul 16, 2029

    granted

  4. US 7563585

    Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)

    Rigel Pharmaceuticals, Inc. · Granted Jul 21, 2009 · Expires Jul 16, 2029

    granted

  5. US 7560466

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Jul 14, 2009 · Expires Jul 9, 2029

    granted

  6. US 7557207

    Spiro 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 7, 2009 · Expires Jul 2, 2029

    granted

  7. US 7557210

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 7, 2009 · Expires Jul 2, 2029

    granted

  8. US 7550460

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jun 23, 2009 · Expires Jun 18, 2029

    granted

  9. US 7538108

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted May 26, 2009 · Expires May 21, 2029

    granted

  10. US 7521192

    EDG: modulators of lymphocyte activation and migration

    Rigel Pharmaceuticals, Inc. · Granted Apr 21, 2009 · Expires Apr 16, 2029

    granted

  11. US 7517886

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Apr 14, 2009 · Expires Apr 9, 2029

    granted

  12. US 7514434

    Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof

    Rigel Pharmaceuticals, Inc. · Granted Apr 7, 2009 · Expires Apr 2, 2029

    granted

  13. US 7511137

    Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates

    Rigel Pharmaceuticals, Inc. · Granted Mar 31, 2009 · Expires Mar 26, 2029

    granted

  14. US 7498435

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 3, 2009 · Expires Feb 26, 2029

    granted

  15. US 7498353

    Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 3, 2009 · Expires Feb 26, 2029

    granted

  16. US 7491732

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Feb 17, 2009 · Expires Feb 12, 2029

    granted

  17. US 7488805

    Apoptosis proteins

    Rigel Pharmaceuticals, Inc. · Granted Feb 10, 2009 · Expires Feb 5, 2029

    granted

  18. US 7485724

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Feb 3, 2009 · Expires Jan 29, 2029

    granted

  19. US 7482351

    4-pyrimidineamine compounds and their uses as anti-proliferative agents

    Rigel Pharmaceuticals, Inc. · Granted Jan 27, 2009 · Expires Jan 22, 2029

    granted

  20. US 7452879

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Nov 18, 2008 · Expires Nov 13, 2028

    granted

  21. US 7449458

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Nov 11, 2008 · Expires Nov 6, 2028

    granted

  22. US 7435814

    2,4-Pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Oct 14, 2008 · Expires Oct 9, 2028

    granted

  23. US 7432047

    Method for selective inactivation of viral replication

    Rigel Pharmaceuticals, Inc. · Granted Oct 7, 2008 · Expires Oct 2, 2028

    granted

  24. US 7423118

    IAPS associated cell cycle proteins, compositions and methods of use

    Rigel Pharmaceuticals, Inc. · Granted Sep 9, 2008 · Expires Sep 4, 2028

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.